Lipoxygenase products in the urine correlate with renal function and body temperature but not with acute transplant rejection

Lipids

Volumn 48, Issue 2, 2013, Pages 167-175

  Reinhold, Stephan W ^a   Scherl, Thomas ^a   Stölcker, Benjamin ^a   Bergler, Tobias ^a   Hoffmann, Ute ^a   Weingart, Christian ^a   Banas, Miriam C ^a   Kollins, Dmitrij ^a   Kammerl, Martin C ^a   Krüger, Bernd ^b   Kaess, Bernhard ^a   Krämer, Bernhard K ^b   Banas, Bernhard ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

12 HETE; 15 HETE; Biomarker; Leukotriene B4; Leukotriene E4; Lipoxygenase product

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; CYCLOSPORIN A; LEUKOTRIENE B4; LEUKOTRIENE E4; LIPOXYGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ENZYME IMMUNOASSAY; ENZYMURIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; LEUKOCYTE COUNT; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ACUTE DISEASE; ADULT; BODY TEMPERATURE; FEMALE; GRAFT REJECTION; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; KIDNEY; KIDNEY TRANSPLANTATION; LEUKOTRIENE B4; LEUKOTRIENE E4; LIPOXYGENASE; MALE; MIDDLE AGED;

EID: 84878353981     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-012-3751-5     Document Type: Article

References (52)

1. Iwamoto H, Hama K, Konno O et al (2012) Early steroid withdrawal in adult kidney transplantation at a single center. Transplant Proc 44:178-181
2. Segoloni GP, Quaglia M (2006) New immunosuppressive drugs for prevention and treatment of rejection in renal transplant. J Nephrol 19:578-586
3. Nankivell BJ, Borrows RJ, Fung CL, OConnell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326-2333
4. US Renal Data System (2010) USRDS 2010 annual data report: atlas of chronic kidney diseases and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
5. Choi BS, Shin MJ, Shin SJ et al (2005) Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 5:1354-1360
6. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
7. Bagshaw SM, Gibney N (2008) Conventional markers of kidney function. Crit Care Med 36:S152-S158
8. Meyer M, Paushter D, Steinmuller DR (1990) The use of duplex Doppler ultrasonography to evaluate renal allograft dysfunction. Transplantation 50:974-978
9. Shoker A, George D, Yang H, Baltzan M (2000) Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. Transplantation 70:497-505
10. Reinhold SW, Straub RH, Krüger B et al (2012) Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation. Cytokine 57:379-388
11. Miller AM, Elfenbein GJ, Barth KC (1989) Regulation of T-lymphopoiesis by arachidonic acid metabolites. Exp Hematol 17:198-202
12. Dinarello CA, Bishai I, Rosenwasser LJ, Coceani F (1984) The influence of lipoxygenase inhibitors on the in vitro production of human leukocyte pyrogen and lymphocyte activating factor (interleukin 1). Int J Immunopharmacol 6:43-50
13. Liu A, Claesson HE, Mahshid Y, Klein G, Klein E (2008) Leukotriene B4 activates T-cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures. Blood 111:2693-2703
14. Sheikh S, Parhar RS, Bakheet R, Saleh S, Collison K, Al-Mohanna F (2004) Immobilisation of rolling NK cells on platelet-borne P-selectin under flow by proinflammatory stimuli, interleukin-12, and leukotriene B4. J Leukoc Biol 76:603-608
15. Atluru D, Goodwin JS (1986) Leukotriene B4 causes proliferation of interleukin-2 dependent T-cells in the presence of suboptimal levels of interleukin-2. Cell Immunol 99:444-452
16. Goodwin JS, Atluru D, Sierakowski S, Lianos EA (1986) Mechanism of action of glucocorticosteroids. Inhibition of T-cell proliferation and interleukin-2 production by hydrocortisone is reversed by leukotriene B4. J Clin Invest 77:1244-1250
17. Mangino MJ, Anderson CB, Deschryver K, Turk J (1987) Arachidonate lipoxygenase products and renal allograft rejection in dogs. Transplantation 44:805-808
18. Sasaki M, Hori MT, Hino T, Golub MS, Tuck ML (1997) Elevated 12-lipoxygenase activity in the spontaneously hypertensive rat. Am J Hypertens 10:371-378
19. Gonzalez-Núnez D, Claria J, Rivera F, Poch E (2001) Increased 12(S)-HETE in patients with essential hypertension. Hypertension 37:334-338
20. Giribaldi G, Prato M, Ulliers D, Gallo V, Schwarzer E, Akide-Ndunge OB et al (2010) Involvement of inflammatory chemokines in survival of human monocytes fed with malarial pigment. Infect Immun 78:4912-4921
21. Farrar WL, Humes JL (1985) The role of arachidonic acid metabolism in the activities of interleukin-1 and -2. J Immunol 135:1153-1159
22. Fogh K, Herlin T, Kragballe K (1988) In vitro inhibition of leukotriene B4 formation by exogenous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils. Arch Dermatol Res 280:430-436
23. Ryan A, Godson C (2010) Lipoxins: regulators of resolution. Curr Opin Pharmacol 10:166-172
24. Levy BD, Zhang QY, Bonnans C, Primo V, Reilly JJ, Perkins DL et al (2011) The endogenous pro-resolving mediators lipoxin A4 and resolving E1 preserve organ function in allograft rejection. Prostaglandins Leukot Essent Fatty Acids 84:43-50
25. Reinhold SW, Vitzthum H, Filbeck T, Wolf K, Lattas C, Riegger GA et al (2006) Gene expression of 5-, 12- and 15-lipoxygenases and leukotriene receptors along the rat nephron. Am J Physiol Renal Physiol 290:F864-F872
26. Spurney RF, Ibrahim S, Butterly D, Klotman PE, Sanfilippo F, Coffman TM (1994) Leukotrienes in renal transplant rejection in rats. Distinct roles of leukotriene B4 and peptidoleukotrienes in the pathogenesis of allograft injury. J Immunol 152:867-876
27. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG et al (2012) Asthma outcomes: biomarkers. J Allergy Clin Immunol 129:S9-S23
28. Samuelsson B, Goldyne M, Granstrom E, Hamburg M, Hammerstrom S, Malmsten C (1978) Prostaglandins and thromboxanes. Annu Rev Biochem 47:997-1029
29. Rola-Plesczynski M, Lemaire I (1985) Leukotrienes augment interleukin 1 production by human monocytes. J Immunol 135:3958-3961
30. Mangino MJ, Mangino JE, Murphy MK, Anderson CB (1996) Arachidonic acid metabolism in intestinal hypothermic preservation injury. Cryobiology 33:404-412
31. Gloor B, Uhl W, Tcholakov O, Roggo A, Muller CA, Worni M et al (2001) Hydrocortisone treatment of early SIRS in acute experimental pancreatitis. Dig Dis Sci 46:2154-2161
32. Jansen NJ, van Oeveren W, van den Broek L, Oudemans-van Straaten HM, Stoutenbeek CP, Joen MC et al (1991) Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 102:515-525
33. Kato K, Murota S (1985) Lipoxygenase specific inhibitors inhibit murine lymphocyte reactivity to CON A by reducing IL-2 production and its action. Prostaglandins Leukot Med 18:39-52
34. Jordan ML, Carlson A, Hoffman RA, Simmons RL (1987) Lipoxygenase pathway inhibition impairs the allograft response. Surgery 102:248-255
35. Mashburn TA Jr, Llanos J, Ahokas RA, Blatteis CM (1986) Thermal and acute-phase protein responses of guinea pigs to intrapreoptic injections of leukotrienes. Brain Res 376:285-291
36. Wenzel SE, Trudeau JB, Westcott JY, Beam WR, Martin RJ (1994) Single oral dose of prednisone decreases leukotriene B4 production by alveolar macrophages from patients with nocturnal asthma but not control subjects: relationship to changes in cellular influx and FEV1. J Allergy Clin Immunol 94:870-881
37. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK et al (1992) Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33:922-928
38. Stenson WF, Cort D, Rodgers J, Burakoff R, DeSchryver-Kecskemeti K, Gramlich TL et al (1992) Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 116:609-614
39. Miller AM, van Bekkum DW, Cobb SM, McCrohan B, Knaan-Shanzer S (1993) Dietary fish oil supplementation alters LTB4:LTB5 ratios but does not affect the expression of graft versus host disease in mice. Prostaglandins Leukot Essent Fatty Acids 49:561-568
40. Gignac MR, Chatlos LJ, Hoffman RA, Gritsch HA, Jordan ML (1997) Genetically determined leukotriene B4 production is not required for cytotoxic effector cell development during allograft rejection. Transplant Proc 29:1052
41. Butterly DW, Spurney RF, Ruiz P, Griffiths R, Albrightson C, Coffman TM (2000) A role for leukotrienes in cyclosporine nephrotoxicity. Kidney Int 57:2586-2593
42. Samuelsson B (1987) An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes. Drugs 33:S2-S9
43. Machida I, Matsuse H, Kondo Y, Kawano T, Saeki S, Tomari S et al (2004) Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J Immunol 172:1833-1838
44. Matsuyama M, Funao K, Chargui J, Touraine JL, Nakatani T, Yoshimura R (2009) The role of cysteinyl-LT(1) receptor (CysLT(1)R) in renal ischemia reperfusion injury. Transplant Proc 41:73-75
45. Wollenberg K, Waibel B, Pisarski P, Rump LC, Kirste G, Krumme B (2000) Careful clinical monitoring in comparison to sequential Doppler sonography for the detection of acute rejection in the early phase after renal transplantation. Transpl Int 13:S45-S51
46. Cahill RA, Zhao Y, Murphy R, Sala A, Foegh M, Spitzer T et al (1991) High urinary leukotriene E4 (LTE4) and thromboxane 2 (TXB2) levels are associated with capillary leak syndrome in bone marrow transplant patients. Adv Prostaglandin Thromboxane Leukot Res 21B:525-528
47. Dolegowska G, Blogowski W, Safranow K, Domanski L, Jakubowska K, Olszewska M (2010) Lipoxygenase-derived hydroxyeicosatetraenoic acids - novel markers of early perioperative markers of early post-transplant allograft function? Nephrol Dial Transplant 25:4061-4067
48. Ma J, Natarajan R, LaPage J, Lanting L, Kim N, Becerra D et al (2005) 12/15-Lipoxygenase inhibitors in diabetic nephropathy in the rat. Prostaglandins Leukot Essent Fatty Acids 72:13-20
49. Antonipillai I, Nadler J, Vu EJ, Bughi S, Natarajan R, Horton R (1996) A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 81:1940-1945
50. Sing H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML (2007) Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50:123-129
51. Regner KR, Zuk A, Van Why SK, Shames BD, Ryan RP, Falck JR, Manthati VL, McMullen ME, Ledbetter SR, Roman RJ (2009) Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int 75:511-517
52. Hoff U, Lukitsch I, Chaykovska L, Ladwig M, Arnold C, Manthati VL, Fuller TF, Schneider W, Gollasch M, Muller DN, Flemming B, Seeliger E, Luft FC, Falck JR, Dragun D, Schunck WH (2011) Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int 79:57-65